| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
COUGH |
1 Center of Excellence for the Study of Inflammation, University of Ferrara, Ferrara, Italy
2 Department of Thoracic-Pumonary Diseases, Unit of Respiratory Physiopathology, University of Bologna, Bologna, Italy
3 Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy
4 Academic Medicine, University of Hull, Hull, UK
Correspondence to:
Correspondence to:
M Trevisani PhD
Center of Excellence for the Study of Inflammation, University of Ferrara, 44100 Ferrara, Italy; tvm{at}unife.it
Background: Iodo-resiniferatoxin (I-RTX) has recently been described as an ultra potent antagonist of the transient receptor potential vanilloid-1 (TRPV1).
Methods: The ability of I-RTX to inhibit cough induced by inhalation of two putative TRPV1 stimulants (capsaicin and citric acid) was tested in non-anaesthetised guinea pigs.
Results: Pretreatment with I-RTX either intraperitoneally (0.03–0.3 µmol/kg) or by aerosol (0.1–3 µM) reduced the number of coughs produced by inhalation of citric acid (0.25 M) and capsaicin (30 µM) in a dose dependent manner. Capsazepine (CPZ) also reduced citric acid and capsaicin induced cough, but the activity of I-RTX was 10–100 times more potent than CPZ in all the experimental conditions tested.
Conclusions: I-RTX is a novel and potent antitussive drug which inhibits cough mediated by agents possibly acting via TRPV1 activation.
Abbreviations: ASIC, acid sensing ion channel; CPZ, capsazepine; I-RTX, iodo-resiniferatoxin; RAR, rapidly adapting receptor; TRPV1, transient receptor potential vanilloid-1
Keywords: cough; guinea pig; vanilloid receptor-1 (TRPV1); iodo-resiniferatoxin (I-RTX)
This article has been cited by other articles:
|
|
 |
|
  A. Bhattacharya, B. P. Scott, N. Nasser, H. Ao, M. P. Maher, A. E. Dubin, D. M. Swanson, N. P. Shankley, A. D. Wickenden, and S. R. Chaplan Pharmacology and Antitussive Efficacy of 4-(3-Trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic Acid (5-Trifluoromethyl-pyridin-2-yl)-amide (JNJ17203212), a Transient Receptor Potential Vanilloid 1 Antagonist in Guinea Pigs J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 665 - 674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Gunthorpe, S. L. Hannan, D. Smart, J. C. Jerman, S. Arpino, G. D. Smith, S. Brough, J. Wright, J. Egerton, S. C. Lappin, et al. Characterization of SB-705498, a Potent and Selective Vanilloid Receptor-1 (VR1/TRPV1) Antagonist That Inhibits the Capsaicin-, Acid-, and Heat-Mediated Activation of the Receptor J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1183 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Gatti, E. Andre, S. Amadesi, T. Q. Dinh, A. Fischer, N. W. Bunnett, S. Harrison, P. Geppetti, and M. Trevisani Protease-activated receptor-2 activation exaggerates TRPV1-mediated cough in guinea pigs J Appl Physiol, August 1, 2006; 101(2): 506 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Canning, D. G. Farmer, and N. Mori Mechanistic studies of acid-evoked coughing in anesthetized guinea pigs Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2006; 291(2): R454 - R463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-G. Lee, B. J. Undem, C. Brown, and M. J. Carr Effect of Nociceptin in Acid-evoked Cough and Airway Sensory Nerve Activation in Guinea Pigs Am. J. Respir. Crit. Care Med., February 1, 2006; 173(3): 271 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G P Anderson TRPV1 and cough Thorax, September 1, 2004; 59(9): 730 - 731. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
